Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: takemasa i. Gastric Cancer. 2017 May;20(3):517-526. doi: 10.1007/s10120-016-0633-1. Epub 2016 Aug 23. Gastric Cancer. 2017. PMID: 27553665 Clinical Trial.
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: takemasa i. Oncology. 2013;85(6):317-22. doi: 10.1159/000356018. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247419 Clinical Trial.
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T, Tamagawa H, Matsuda C, Murata K, Fukunaga M, Ota H, Hasegawa J, Tsujie M, Fukuzaki T, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: takemasa i. Oncology. 2015;89(3):152-8. doi: 10.1159/000381718. Epub 2015 May 8. Oncology. 2015. PMID: 25967649 Clinical Trial.
Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C, Uemura M, Nakata K, Shingai T, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, Ikeda M, Ohue M, Murata K, Hasegawa J, Satoh T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Matsuda C, et al. Among authors: takemasa i. BMC Cancer. 2015 Jun 3;15:452. doi: 10.1186/s12885-015-1476-6. BMC Cancer. 2015. PMID: 26036466 Free PMC article. Clinical Trial.
Erratum to: Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: takemasa i. Gastric Cancer. 2017 May;20(3):527. doi: 10.1007/s10120-016-0643-z. Gastric Cancer. 2017. PMID: 27629880 No abstract available.
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y, Hirakawa M, Ohnuma H, Takahashi M, Okamoto T, Okamoto K, Miyamoto H, Muguruma N, Furuhata T, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: takemasa i. Cancer Chemother Pharmacol. 2017 Dec;80(6):1133-1139. doi: 10.1007/s00280-017-3458-7. Epub 2017 Oct 16. Cancer Chemother Pharmacol. 2017. PMID: 29038850
341 results